Literature DB >> 2022448

Selective use of low-osmolar contrast media.

J F Debatin1, R H Cohan, R A Leder, C B Zakrzewski, N R Dunnick.   

Abstract

Two thousand thirty-four consecutive patients presented for excretory urography within a 22-month period. Of 57 observed adverse reactions (incidence 2.8%), 54 occurred in 1219 low-risk patients injected with conventional ionic contrast media (HOCM) (incidence 4.4%) while three reactions were noted in the 815 high-risk patients receiving low-osmolar contrast media (LOCM) (incidence 0.4%). Despite strict enforcement of an unchanging list of high-risk criteria by the same pool of radiologists, LOCM use was not constant, increasing in use over time from 26.5% to 55.3% of urograms. In addition, frequency of LOCM selection increased transiently (from 33% to 52%) following a single life-threatening reaction to HOCM. Our results suggest that strict guidelines for use of LOCM are subject to loose individual physician interpretation. Physicians' perceptions of safety made it increasingly difficult to withhold LOCM and progressively more patients were included in high-risk groups.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022448     DOI: 10.1097/00004424-199101000-00004

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  3 in total

Review 1.  Reactions to radiocontrast material. Anaphylactoid events in radiology.

Authors:  P L Lieberman; R L Seigle
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

2.  Improvement of parenchymal and vascular enhancement using saline flush and power injection for multiple-detector-row abdominal CT.

Authors:  Helmut Schoellnast; Manfred Tillich; Hannes A Deutschmann; Uwe Stessel; Michael J Deutschmann; Gottfried J Schaffler; Renate Schoellnast; Martin M Uggowitzer
Journal:  Eur Radiol       Date:  2003-10-18       Impact factor: 5.315

3.  Selective use of low-osmolality contrast media in computed tomography.

Authors:  Carlos Valls; Eduard Andía; Anna Sánchez; Victor Moreno
Journal:  Eur Radiol       Date:  2001-12-13       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.